

Vasoactive agents in liver transplant anesthesia: <u>hemodynamic optimization tactics</u>

Alexander A. Vitin, MD, Ph.D Head, Transplant Anesthesia Division, University of Washington Medical Center, Seattle, WA, USA

Liver transplantation stats



2013

SWORld Health

Organization

TON

BALKAN

Europe

- Approx. 25,000 liver transplants were conducted g
- More than 5,500 liver transplants are perform
- Cirrhosis is the beacting cause of adult over transplate
- Based on clata from the performed in 28 countries between 1968 and 2014
- 1-year survey and the structure of the World Health Organization is used on this map to not imply the expression of any opinion, with its ever on the part of the World Health Organization concerning the legal status of any country, territory, city or age or of its authorities. Data source: GLO map production with structure and the initiation of the structure of the world Health Organization of
- 5-year surv
- Many recipients^{ARBEIN}g for up to 20° years^{an}

Where we are, who we are, what we do









Disclosure

Regretfully, I have nothing to disclose:no financial/vested interestsno conflict of interests

I have interest in research and practice improvement only

Presentation outline



- Hemodynamic regulation in the End-Stage Liver Disease patient
- Factors contributing to the hemodynamic profile



 Hemodynamic optimization: what, when, and how to correct



Vaso-active agents use

Anesthesia setup I







Monitoring:

Routine : ECG, Non-invasive BP, Pulse oxymetry ; arterial line (1 or 2)

PA (Swan-Ganz) catheter: CO, CI, SVR, SvO₂

TEE

Bi-spherical Index (BIS)

Thrombo-elastography: PT/PPT, INR, PLT and more

Anesthesia setup II



Vascular access and volume management Large-bore triple-lumen catheter/PA introducer in IJ **Belmont® rapid infusion** pump **Maintenance** Isoflurane Fentanyl continuous infusion, 3-5 mcg/kg/h **Cis-Atracurium infusion**, 0.8-1 mcg/kg/min



Hemodynamic goals

- MAP : 75-85 mmHg
- HR: <100/min
- CVP: < 20 mmHg
- MPAP: <25 mmHg
- CO/CI: >4 L/min / >2 L/min*m²
- SVR: > 500 dynes / sec / cm⁻⁵
- Mixed Venous SvO2: >75%

Vasomotor tone regulation in ESLD: vasoplegia



- Cardiovascular response to catecholamines
 is substantially attenuated in ESLD patients
 - Sensitivity of β-adrenorecpetors is relatively decreased
- Plasma free norepinephrine and epinephrine levels are significantly higher
- Fraction of epinephrine contributing to total catecholamines increased up to 50% (normal: about 17%)
- Dopamine concentration is unchanged
- As a result, systemic vasoplegia due to low SVR is typical for ESLD

Hepatic Blood Flow: Impact of Anesthesia-related factors

Increase:

- Dopamine,
 (3mcg/kg/min)
 Hypercapnia
- Acidosis
- Hypoxemia
 (+/-)



Decrease:

- PPV (+PEEP)
- β blockers, α -
- agonists, H₂ blockers
- Hypocapnia
- Alkalosis
- Hyperglycemia

- All anesthetic techniques in the absence of surgical stimulation decrease HBF by 30%.
- Isoflurane, Sevoflurane and Desflurane maintain HBF
- Fentanyl has no effect on HBF



Dissection phase

Drop of intra-abdominal pressure

Laparotomy ascites evacuation

Decrease of venous return

Rapid splanchnic volume increase (mesenteric blood pooling)

Blood loss, fluid shift, acidosis



Anhepatic phase: Portal and Caval cross-clamp





 Portal clamp: drop of venous return is variable (loss of 20-30% of baseline venous return)

- With developed porto-caval collaterals (long-standing portal hypertension) –loss of 15 to 20% of pre-clamp venous return
- IVC complete clamp : approximately 50% decrease of venous return
- IVC partial clamp: variable, 25 50% decrease of venous return

Veno-venous bypass (VVB)



 VVB provides flow rates ranged from 1.5 to 3.6 L/min

- VVB is advocated in cases:
 - total IVC clamp
 - 30% drop in MABP

- 50% decrease in CI during 5 min test- IVC cross-clamping period

Veno-venous bypass: pro' and contra'

 \bullet





- Preserving the CO/CI, maintaining hemodynamic stability
- Maintaining CBF, especially in FHF cases
- Maintaining the RBF and kidney function (?)
- Longer anhepatic phase.
- Blood loss reduction (?)
- Improving the clinical outcome (?)
- Lower lactate

- Pulmonary air emboli, thrombosis
 - No evidence of maintaining normal perfusion of abdominal organs and preserving renal function
 - Longer operative and warm ischemia time
 - Higher rate of post-reperfusion syndrome
- Increasing bleeding
- No evidence for improving the clinical outcome
- Higher procedure cost

Liver graft reperfusion

Myocardial injury: arrythmias, asystolic arrest

Temperature

drop.ck.

lactic

acidosis



Decrease of CO/CI, **SVR and MABP**

Decreased sensitivity to catecholamines **/vasoactive agents**

Blood loss

Hemodilution Anemia, hypovolemia

Coagulation Fibrinolysis **Factors deficit** +consumption, Clot strength **Fibrinolysis**

RV overload

PAP and CVP

ncrease

ALI

interstitial

oedema

Post-reperfusion syndrome



 PRS is defined as a: - > 30% of MABP decrease from that in the anhepatic stage, - for longer than for 1 min, during the first 5 min after reperfusion of the liver graft.



Lactic Acidosis in ESLD may be beneficial!



- Decreased synthesis of hepatic pyruvate dehydrogenase, hence impaired lactate – to – bicarbonate conversion
- Acidosis itself decreases lactate clearance
- Severe LA (lactate > 5 mEq/l) is associated with mortality rates 50-56%
- Short duration acidosis prevents anoxic cell death, and reoxygenation at convergences cell toxicity
- Reperfusion at low pH blocks increase of mitochondrial membrane permeability, which allows mitochondrial repolarization and prevents cell death

Lactate during liver transplant



(Vitin A. et al., 2010)



Porto-pulmonary syndrome

Parameters	Value
MPAP	>25 mmHg at rest >30 mmHg with exercise/stress
PCWP	<15 mmHg
PVR	>120 dynes/sec/cm ⁵
Trans-pulmonary gradient	> 10 mmHg

	Normal	Mild	Moderate	Severe	
NYHA class	_	I, II	II, III	III, IV	
Mean pulmonary arterial pressure (mm Hg)	15-24	25-34	35-44	>45	
Cardiac index (L min-1 m-2)	2.5-4.0	>2.5	>2.5	<2.0	
Pulmonary vascular resistance (dyne s-1 cm-5)	<240*	240-500	500-800	>800	
Right arterial pressure (mm Hg)	0-5	0-5	5-8	>8	
Prognosis	-	Favourable	Questionable	Poor	
Specific treatment required+	-	No	Questionable	Yes	
Reversibility after liver transplantation	-	Yes	Questionable	No	

Intra-operative Pulm HTN management





- Fluid restriction (especially crystalloids)
- Diuretics (Furosemide, not Mannitol)
- Nitroglycerine infusion, 1-1.5 mcg/kg/min
- Epoprostenol, 2-12 mcg/kg/min
- CVVH / hemodialysis
- Nitric Oxide inhalation 20-25 ppm
 - Vasopressin decreases PAP while maintaining systemic MABP

Blood loss: predisposing factors

Changing trends in transfusion practice in liver transplantation Yves Ozier^a and Mei-Yung Tsou^b

Predictors of Blood Product Use in Orthotopic Liver Transplantation Using the Piggyback Hepatectomy Technique

R.S. Mangus, S.B. Kinsella, M.M. Nobari, J.A. Fridell, R.M. Vianna, E.S. Ward, R. Nobari, and A.J. Tector

Intraoperative Massive Transfusion Decreases Survival After Liver Transplantation

I.F.S.F. Boin, M.I. Leonardi, A.C.M. Luzo, A.R. Cardoso, C.A. Caruy, and L.S. Leonardi

10. Surgeon-related factors...



- 1. MELD score >25
- 2. Portal hypertension
- 3. Pre-existing + ongoing consumption & dilution coagulopathy
- 4. Long, traumatic liver dissection
- 5. "Hostile abdomen" s/p laparotomy
- 6. Re-do OLT
- 7. Long ischemia times
- 8. Aged/marginal quality donor organ
- 9. Donor-recipient organ size discrepancy

Hemotransfusion during OLT





- Different surgical techniques, anesthesia protocols, transfusion triggers and institutional practices
- RBCs use: 10 y. ago 20 units, currently: 1-5 to 0 (average)
- Modern trends: restriction of RBCs and other blood products use to absolutely necessary minimum; use of Cell Saver
- Massive RBCs, FFP and PLT transfusions are independent predictors of negative impact on recipient and graft survival

Ways of blood loss reduction



 Piggy-back technique with IVC preservation – partial IVC clamp

2. Maintaining the low CVP (controversial)

3. Minimum hemodilution: limit crystalloids infusion

4. Vasoactive agents use

"Low CVP" paradigm l



LIVER TRANSPLANTATION 12:117-123, 2006

ORIGINAL ARTICLE

Effect of Low Central Venous Pressure and Phlebotomy on Blood Product Transfusion Requirements During Liver Transplantations

Luc Massicotte,¹ Serge Lenis,¹ Lynda Thibeault,¹ Marie-Pascale Sassine,¹ Robert F. Seal,² and André Roy³

¹Department of the Centre Hospitalier de l'Université de Montréal (CHUM); ²Department of Anesthesiology and Pain Medicine of the University Alberta; and ³Department Of Surgery, Hepato-biliary Service, of the CHUM

To maintain CVP around 5-7 mmHg:

- crystalloid, colloid and blood products volume restrictions,
- diuretics,
 - Nitroglycerine
- Anti-Trendelenburg
 position

"Low CVP" paradigm II

Pro: potential for blood loss decrease

- lowered transfusion requirements
- oxygen delivery improvement to the liver graft by creating a greater MABP/CVP gradient

Contra:

- Increased post-op renal failure
- Increased 30-days mortality
- increased dosage of vasopressors - > peripheral vasoconstriction
- promoting metabolic acidosis

"CVP decrease should be avoided in liver transplant patients" (Ozier Y et al., 2008)

Vasoactive agents use



- Routine use (doses in mcg/kg/min):
- Phenylephrine, 0.01 1.5
- Norepinephrine, 0.01-0.5
- Optional:
- Epinephrine, 0.01 0.05
- Dopamine, 3
- Vasopressin, 0.04 U/min





Vasopressin

- Increases SVR, decreases MPAP, normalizes CO/CI, and, potentially, CVP.
- Maintains mean BP
- Decreases portal pressure, HBF and SBF
- Improves impaired renal function, enhances diuresis, thus improves Na balance and lactate elimination
- Enhances platelet aggregation and increases levels of Pro- factor VIII and von Willebrand factor
- Does not promote lactic acidosis
- Seems to be able to decrease blood loss during pre- and anhepatic phases of OLT

Vasoactive agents timing/dosage during OLT



Vasopressin in OLT

Liver Transpl Surg. 1997 Jul;3(4):379-87. Circulatory pathophysiology and options in hemodynamic management during adult liver transplantation.

Mandell MS, Katz JJ, Wachs M, Gill E, Kam I. Department of Anesthesiology, University of Colorado, Health Science Center, Denver 80262, USA.

> The Use of Vasopressin Bolus to Treat Refractory Hypotension Secondary to Reperfusion During Orthotopic Liver Transplantation Jonathan V. Roth, MD

LIVER TRANSPLANTATION 14:1664-1670, 2008

ORIGINAL ARTICLE

Vasopressin Decreases Portal Vein Pressure and Flow in the Native Liver During Liver Transplantation

Gebhard Wagener,¹ Gina Gubitosa,¹ John Renz,² Milan Kinkhabwala,² Tricia Brentjens,¹ James V. Guarrera,² Jean Emond,² H. Thomas Lee,¹ and Donald Landry³ Departments of ¹Anesthesiology, ²Surgery, and ³Medicine, College of Physicians and Surgeons, Columbia University, New York, NY

The Development of Perioperative Practices for Liver Transplantation: Advances and Current Trends

Merceds Susan Mandell¹, Mei-Yung Tsou²* ¹Department of Anesthesiology, University of Colorado Health Sciences Center, Aurora, Colorado, U.S.A., and ²Department of Anesthesiology, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.

injury. Anesthesiologists found that they could use vasoconstrictors to increase systemic vascular resistance during surgery, which in turn improved blood pressure and organ perfusion.²² Anesthesiologists also borrowed techniques from the field of hepatology that specifically controlled splanchnic blood flow.²³ Anesthesiologists discovered that intra-abdominal blood loss would be reduced by limiting splanchnic blood flow during surgery.²⁰ Drugs used to control variceal bleeding such as vasopressin are now commonly used during surgery to selectively limit blood flow to the gut in order to reduce surgical bleeding.24 Control of the circulatory system made the use of venovenous bypass optional.25 This reduced the anhepatic time, along with the cold ischemic and total surgical time-factors that are strongly correlated with outcome.²⁶ These

J Chin Med Assoc • September 2008 • Vol 71 • No 9

Hemodynamic effects of low-dose vasopressin vs phenylephrine



Vitin AA, Martay K, Vater Y, Dembo G, Maziarz M (2010) Effects of Vasoactive Agents on Blood Loss and Transfusion Requirements During Pre-Reperfusion Stages of the Orthotopic Liver Transplantation. J Anesthe Clinic Res 1:104 doi:10.4172/2155-6148.1000104

Vasopressin vs phenylephrine & epinephrine effect on blood loss



• The EBL before liver graft reperfusion 50.2% lower (p=0.0094) and TBL 38.8% lower (p=0.0548), than in control (Phenyl/Epinephrine) group (Vitin A et al.,2010)

Conclusions

Phenylephrine may be a first choice

 Vasopressin may be used during dissection and anhepatic stages; use after reperfusion remains controversial.



Epinephrine may be used throughout, but should be discontinued ASAP



 Albeit efficient, Norepinephrine appears to be the less suitable drug



 Nitroglycerine may be effective for postreperfusion PAP surge correction



Welcome to Seattle!